Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Abstract

In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated <i>KRAS</i> p.G12C-mutated NSCLC. (Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).

Keywords

MeSH Terms

Affiliated Institutions

• Virginia Cancer Specialists US
• Johns Hopkins Medicine US
• HealthONE US
• University Health Network CA
• Integrated Oncology (United States) US
• Kanagawa Cancer Center
• Woodlands Hospital GB
• Shizuoka Cancer Center JP
• Emory University US
• The University of Texas MD Anderson Cancer Center US
• University Hospital Cologne DE
• Weill Cornell Medicine US
• Princess Margaret Cancer Centre CA
• Roswell Park Comprehensive Cancer Center US
• Sarah Cannon Research Institute GB
• German Cancer Research Center DE
• Kanagawa Prefectural Hospital Organization JP
• Deutschen Konsortium für Translationale Krebsforschung
• The University of Adelaide AU
• University Hospital of Zurich CH
• Institut Gustave Roussy FR
• Fox Chase Cancer Center US
• Amgen (United States) US
• Institut Bergonié FR
• Cancer Institute (WIA) IN
• New York University US
• Alvin J. Siteman Cancer Center
• Cornell University US
• Johns Hopkins University US
• Memorial Sloan Kettering Cancer Center US
• Queen Elizabeth Hospital AU

Related Publications